 |
|
|
| |
Nivolumab in Sorafenib-Experienced Patients With Advanced Hepatocellular Carcinoma With or Without Chronic Viral Hepatitis: CheckMate 040 Study
|
| |
| |
Download the PDF here
Reported by Jules Levin
EASL 2017 April 19-22 Amsterdam Netherlands
Bruno Sangro,1 Thomas Yau,2 Chiun Hsu,3 Masatoshi Kudo,4 Todd S. Crocenzi,5 Su-Pin Choo,6 Tim Meyer,7 Theodore H. Welling, III,8 Winnie Yeo,9 Akhil Chopra,10 Adyb Baakili,11 Christine dela Cruz,11 Lixin Lang,11 Jaclyn Neely,11 Ignacio Melero,12,13
Anthony B. El-Khoueiry,14 Jörg Trojan15
1Clinica Universidad de Navarra and CIBEREHD, Pamplona, Spain;
2University of Hong Kong, Hong Kong, China; 3National Taiwan University Hospital, Taipei, Taiwan;
4Kindai University Faculty of Medicine, Osaka, Japan; 5Providence Cancer Center, Portland, OR, USA;
6National Cancer Center, Singapore; 7Royal Free Hospital, London, UK; 8University of Michigan School of Medicine, Ann Arbor, MI, USA;
9Chinese University of Hong Kong, Hong Kong, China; 10Johns Hopkins Singapore International Medical Centre, Singapore;
11Bristol-Myers Squibb, Princeton, NJ, USA; 12Clinica Universidad de Navarra and CIBERONC, Pamplona, Spain;
13Center for Applied Medical Research (CIMA), Pamplona, Spain;
14USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA;
15Goethe University Hospital and Cancer Center, Frankfurt, Germany
1. International Agency for Research on Cancer. GLOBOCAN 2012 v1.0. http://globocan.iarc.fr/Pages/fact_sheets_population.aspx. Accessed March 31, 2017. 2. McGlynn KA et al. Clin Liver Dis. 2015;19:223-238.
|
| |
|
|
|
|
|
